Read our latest updates & insights

During its Q4/2025 Earnings Call on 19 March 2026, Alvotech provided updates on its launch plans and regulatory applications for various biosimilars, including golimumab, aflibercept, vedolizumab and pembrolizumab.

Alvotech confirmed that Gobivaz® (AVT05) was launche...

On 19 March 2026, Formycon and Klinge announced they have entered into a settlement and licence agreement with Regeneron/Bayer for FYB203, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), 2mg, in Europe and key markets in the Latin American and Asia-Pacific regions.  T...

On 18 March 2026, Sandoz announced it has entered into a licence, development and commercialisation agreement with Samsung Bioepis for up to five biosimilars, including vedolizumab.

Under the agreement, Sandoz will have exclusive rights to commercialise the biosimila...

On 17 March 2026, Celltrion announced that the subcutaneous (SC) formulation of Avtozma®, biosimilar to Roche’s Actemra® (tocilizumab), is now available in the US.  The SC formulation is approved for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopat...

On 16 March 2026, Samsung Bioepis and its sister company, Epis NexLab, announced they have entered into a research collaboration and licence agreement with G2GBIO to develop long-acting semaglutide.  G2GBIO specialises in the development of sustained-release formulations us...

On 13 March 2026, Novartis received FDA approval for Cosentyx® (secukinumab) for the treatment of moderate to severe Hidradenitis Suppurativa (HS) in paediatric patients aged 12 years and older.  According to Novartis, Cosentyx® is the only IL-17A inhibitor approved for thi...

On 13 March 2026, IAM reported that Regeneron has applied to a US Court to seek discovery of manufacturing-related documents from Sam Chun Dang’s (SCD’s) US subsidiaries for use in its patent infringement litigation in Taiwan regarding SCD’s biosimilar to Regeneron’s Eylea®...

On 13 March 2026, Sandoz filed an appeal with the US Court of Appeals for the Fourth Circuit, challenging the dismissal of the antitrust proceeding it had commenced in April 2025 alleging that Amgen “unlawfully extended and entrenched its monopoly” for Enbrel® by “blocking ...